RT Journal Article
SR Electronic
T1 Monoclonal antibody and antiviral therapy for treatment of mild-to-moderate COVID-19 in pediatric patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.03.16.22272511
DO 10.1101/2022.03.16.22272511
A1 Vora, Surabhi B.
A1 Englund, Janet A.
A1 Trehan, Indi
A1 Waghmare, Alpana
A1 Kong, Ada
A1 Adler, Amanda
A1 Zerr, Danielle M.
YR 2022
UL http://medrxiv.org/content/early/2022/03/18/2022.03.16.22272511.abstract
AB The recent surge of SARS-CoV-2 Omicron variant (B.1.1.529) coincided with new treatment options for mild-to-moderate Covid-19 in high-risk adolescents and adults. In this report we describe patient characteristics, treatment-related process measures and outcomes associated with early Covid-19 therapy in high-risk pediatric patients.Competing Interest StatementJAE receives research support from AstraZeneca, GlaxoSmith Kline, Merck, and Pfizer, and is a consultant for AstraZeneca, Sanofi Pasteur, and Meissa Vaccines. AW reports grant support from Ansun Biopharma, Allovir, VB Tech, and Amazon Inc, and is an Advisory Board Member for Kyorin Pharmaceutical. All other authors have no conflicts of interest relevant to this work to disclose.Funding StatementThe study did not receive any funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The IRB of Seattle Children's Hospital gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study will be available upon reasonable request to the authors after peer review and publication of the final article.